Company: GHRS
Filing Date: 2025-10-17
Form Type: 6-K
Source: 0001140361-25-038374
Chunk: 0

Company: GH Research PLC
Filing Date: 2025-10-17
Form: 6-K
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

| Form 20-F | ☒ |     | Form 40-F | ☐ |

GH Research PLC announces the acceptance of posters related to its GH001-TRD-201 clinical trial at the 64 thAmerican College of Neuropsychopharmacology (ACNP) annual meeting (the “ Congress”), which is scheduled to take place from January 12-15, 2026, in Nassau, Bahamas. A copy of the abstract for the poster to be presented by Sanjay J. Mathew during the Congress is attached hereto as Exhibit 99.1. A copy of the abstract for the poster to be presented byLisa Harding during the Congress is attached hereto as Exhibit 99.2. A copy of the abstract for the poster to be presented byAndreas Reif during the Congress, is attached hereto as Exhibit 99.3. 1

EXHIBIT INDEX

| 99.1 | Abstract for posterto be presented by Sanjay J. Mathew with Title: Suicidal Ideation and Behavior in Patients With Treatment-Resistant Depression Treated With GH001 |
| 99.2 | Abstract for posterto be presented by Lisa Harding with Title:Rapid Antidepressant Effects of Inhaled GH001 in Treatment-Resistant Depression: Results               
 from a Phase 2b, Double-Blind, Randomized Controlled Trial with 6-Month Follow-Up                                                                                    |
| 99.3 | Abstract for posterto be presented by Andreas Reif with Title:Efficacy and Safety of Inhaled Mebufotenin (GH001) in Patients                                         
 with Bipolar II Disorder and a Current Major Depressive Episode: Results from a Phase 2a Clinical Trial                                                              |

2

SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934